New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
09:15 EDTMRK, IRDM, NVS, CCL, ARX, ODP, DKS, ECYT, CLVS, OPHT, ACXM, URBN, SPLS, LIVE, DNDN, GPK, TJX, ICPT, CABOn The Fly: Pre-market Movers
HIGHER: Aeroflex (ARX), up 25% after agreeing to be acquired by Cobham for about $1.46B... Clovis (CLVS), up 6.6% after receiving breakthrough therapy designation for CO-1686... Ophthotech (OPHT), up 17.6% after entering into an ex-U.S. licensing, commercialization agreement with Novartis (NVS) for Fovista... Dendreon (DNDN), up 9% after announcing presentation of PROVENGE ProACT, IMPACT studies data... Iridium (IRDM), up 5% after upgraded at Raymond James... Acxiom (ACXM), up 3% after upgraded at Wells Fargo... Carnival (CCL), up 2% following upgrade at Morgan Stanley. DOWN AFTER EARNINGS: Dick's Sporting (DKS), down 15%. Peer Cabelas (CAB) also down 2% after Dick's report... Staples (SPLS), down 10%. Peer Office Depot (ODP) also down 2.6% after Staples' report... Urban Outfitters (URBN), down 4%... TJX (TJX), down 4.7%. ALSO LOWER: Intercept (ICPT), down 5.8% after The Street reported that the company knew of abnormal cholesterol levels in patients taking its liver disease drug obeticholic acid... Graphic Packaging (GPK), down 3% after offering 43.65M shares of common stock for holders... LiveDeal (LIVE), down 15% after entering 10M share common stock distribution agreement... Endocyte (ECYT), down 5% after company and partner Merck (MRK) withdraw CMA for vintafolide in Europe.... Molycorp (MCP), down 2.5% after downgraded at Morgan Stanley.
News For DKS;CAB;SPLS;ODP;ICPT;URBN;ARX;TJX;ACXM;CCL;GPK;OPHT;NVS;DNDN;CLVS;IRDM;LIVE;ECYT;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 14, 2015
07:36 EDTDKSDick's Sporting backs Q1 EPS 49c-53c, consensus 53c
Subscribe for More Information
07:36 EDTDKSDick's Sporting expects to invest $850M in net CapEx over next three years
DICK'S Sporting Goods also reaffirmed its capital allocation strategy to provide returns to shareholders through investing in the business, repurchasing shares and paying dividends. To drive the growth of the business the company expects to invest approximately $850M in net capital expenditures over the next three years, primarily in new stores, store remodels and eCommerce. With its $1B 5-year share repurchase authorization, the company targets share repurchases of $100 to 200 million annually. The company is also committed to quarterly dividends.
07:35 EDTDKSDick's Sporting expects to open 9 Specialty Concept stores in 2015
Subscribe for More Information
07:34 EDTDKSDick's Sporting plans to have ecommerce site on own platform in January 2017
Subscribe for More Information
07:34 EDTDKSDick's Sporting sees significant opportunity to increase market share in US
The company sees significant opportunity to increase market share in the U.S. through growing its DICK'S Sporting Goods store base in new and underpenetrated markets and increasing its eCommerce sales. Stores continue to be a very profitable growth vehicle that deliver strong new store productivity, accelerate eCommerce growth, build brand equity and customer loyalty, and reinforce the strength of the Company's vendor partnerships. The company is taking a measured approach to growing its store count and anticipates growing its DICK'S Sporting Goods store base to approximately 735 to 750 stores by the end of fiscal 2017, an increase of approximately 135 to 150 stores from the 603 stores at the end of fiscal 2014. The company plans to grow eCommerce sales to approximately $1B-1.2B in fiscal 2017, from $628 million in fiscal 2014.
07:32 EDTDKSDick's Sporting sees FY17 revenue $8.7B-$9B, 3-year EPS CAGR of 12%-16%
Subscribe for More Information
06:29 EDTURBNUrban Outfitters upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information
April 13, 2015
16:51 EDTNVSDiplomat Pharmacy to dispense Novartis' JADENU
Diplomat Pharmacy is set to distribute JADENU, a drug recently approved by the U.S. FDA to treat patients with chronic iron overload. JADENU is a new oral formulation of EXJADE for the treatment of chronic iron overload due to blood transfusions in patients age 2 and older, and chronic iron due to NTDT in patients age 10 and older.
16:21 EDTCLVSOn The Fly: Top stock stories for Monday
Subscribe for More Information
11:28 EDTSPLS, ODPStarboard CEO says Staples, Office Depot merger 'likely to go through'
Says confident the potential merger will pass anti-trust scrutiny. Jeff Smith is speaking on CNBC.
10:15 EDTCLVSHigh option volume stocks
Subscribe for More Information
10:00 EDTCLVSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTCLVSOn The Fly: Pre-market Movers
HIGHER: Builders FirstSource (BLDR), up 54.35% after acquiring ProBuild in all-cash transaction... Arrowhead (ARWR), up 14.3% after being cleared to proceed with multiple dose Phase 2b study of ARC-520... Oramed Pharmaceuticals (ORMP), up 6.9% after enrolling first patient in glucose clamp study for oral insulin... Clovis Oncology (CLVS), up 8.2% after being upgraded to Buy from Neutral at Goldman... Quantum (QTM), up 3.2% after announcing go-to-market partnership with Dot Hill Systems (HILL)... Netflix (NFLX), up 3.4% after being upgraded to Buy from Neutral at UBS... Apple (AAPL), up just under 1% following reports of Apple Watch orders. LOWER: Sina (SINA), down 3% following a report from the Financial Times that China may shut down the company if censorship doesn't improve... Ruckus Wireless (RKUS), down 2.9% after being downgraded to Buy from Conviction Buy at Goldman... Allot Communications (ALLT), down 2.7% after being downgraded to Hold from Buy at Needham.
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:32 EDTDKSUnder Armour rises after Spieth brings attention to golf gear
Subscribe for More Information
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:43 EDTCLVSClovis upgraded to Buy from Neutral at Goldman
Subscribe for More Information
06:22 EDTURBN, TJXGap, Target, others scrutinized by NY AG over staffing practices, WSJ says
Several major retailer including Gap (GPS) and Target (TGT) are under investigation by New York Attorney General Eric Schneiderman over their staffing practices and whether they require workers to show up or stay home with little notice, The Wall Street Journal reports. Schneiderman sent letters warning Abercrombie & Fitch (ANF), JC Penney (JCP), Urban Outfitters (URBN), TJX Cos (TJX), Ann Inc (ANN), L Brands (LB), Burlington Stores (BURL), Sears Holdings (SHLD), Williams-Sonoma (WSM) and J Crew Group that he believes the chains are using on-call scheduling and that such practices may be in violation of New York laws. Reference Link
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information
05:21 EDTNVSNovartis to present new data that confirms high efficacy of Gilenya
Novartis announced new Gilenya analyses to be presented at the 67th American Academy of Neurology, or AAN, Annual Meeting in Washington, DC, from April 18-25, showing how Novartis is advancing methods assessing the impact of relapsing multiple sclerosis, or RMS, for patients and physicians. Data will show how adding brain shrinkage to an existing tool to assess MS disease activity will give a more precise prediction of the likelihood of future disability progression. Accurate assessment of disease activity is key to guide treatment decisions in RMS. A pooled analysis from the two-year phase III FREEDOMS and FREEDOMS II trials will further confirm Gilenya's high efficacy in previously-treated patients with highly-active RMS in achieving 'no evidence of disease activity' across four key measures: relapses, MRI lesions, brain shrinkage and disability progression. Achieving NEDA4 is especially critical for highly-active RMS patients, who are likely to lose more physical and cognitive functions over time despite being treated.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use